Connect Biopharma Holdings Ltd
CNTB evidence brief
What we can confirm
- BioSniper Score:
- 6.2 / 10
- Market Cap:
- $128.5M
- Lead Asset:
- rademikibart (Phase 2)
What it means
What to watch
Prepared research question
What matters most for CNTB—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CNTB
Connect Biopharma Holdings Ltd (CNTB) is a clinical-stage biopharmaceutical company developing rademikibart, a next-generation anti-IL-4Rα antibody, for acute exacerbations in asthma and COPD, with positive Phase 2 topline data reported in September 2026.
Key risk: No approved products
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 3 clinical trials for Connect Biopharma Holdings Ltd.
Connect Biopharma Holdings Ltd (CNTB) is a clinical-stage biopharmaceutical company developing rademikibart, a next-generation anti-IL-4Rα antibody, for acute exacerbations in asthma and COPD, with positive Phase 2 topline data reported in September 2026.
- Cash & equivalents of $27.0M as of 2026-06-30 [sec].
- Total revenue of $2.8M and net income of -$17.3M as of 2026-06-30 [sec].
- Phase 2 Seabreeze STAT asthma study: rademikibart reduced treatment failure at 28 days by 66% vs. placebo [news · 2026-09-15].
- Phase 2 Seabreeze STAT COPD study: rademikibart reduced treatment failure at one month by 81% (p=0.0122) and new moderate-to-severe exacerbations by 85% (p=0.030) [news · 2026-09-30].
- Cash runway expected for at least one year from August 2026 [news · 2026-08-12].
What works
- Positive Phase 2 topline data for rademikibart in both asthma (66% reduction in treatment failure) and COPD (81% reduction in treatment failure) [news · 2026-09-15][news · 2026-09-30].
- Rademikibart was well tolerated with a low incidence of adverse events in both asthma and COPD studies [news · 2026-09-15][news · 2026-09-30].
- Cash runway expected for at least one year from August 2026, providing financial stability for near-term operations [news · 2026-08-12].
- Company plans to discuss a Phase 3 registrational program with the FDA for rademikibart in COPD [news · 2026-09-30].
What to weigh
- Net income of -$17.3M as of 2026-06-30 indicates ongoing operating losses [sec].
- Total revenue of only $2.8M as of 2026-06-30 reflects no approved product sales [sec].
- Phase 2 data are preliminary and require confirmation in larger Phase 3 trials before regulatory submission.
- Competitive landscape includes standard-of-care treatments (bronchodilators, corticosteroids) for acute exacerbations [pipeline].
From the filings
Quoted directly from source documents.
Phase 2 asthma study showed 66% reduction in treatment failure at 28 days
“Rademikibart meaningfully reduced the rate of treatment failure at 28 days by 66% compared to placebo”
News · September 15, 2026
Phase 2 COPD study showed 81% reduction in treatment failure at one month
“Rademikibart significantly reduced the rate of treatment failure compared to placebo through one month by 81% (p=0.0122)”
News · September 30, 2026
Cash runway expected for at least one year from August 2026
“Cash runway expected for a period of at least one year from the date of this release”
News · August 12, 2026
Company plans to discuss Phase 3 program with FDA
“Connect Biopharma said it plans to discuss a Phase 3 registrational program with the FDA”
News · September 30, 2026
Catalyst timeline
- 2025-08-08 · Phase 2 start for rademikibart in asthma acute exacerbations — A Phase 2 trial evaluating rademikibart as add-on treatment for acute exacerbations in asthma patients with type 2 inflammation began.
- 2025-08-12 · Phase 2 start for rademikibart in COPD acute exacerbations — A Phase 2 trial evaluating rademikibart as add-on treatment for acute exacerbations in COPD patients with type 2 inflammation began.
- 2026-06-30 · Phase 2 topline data expected — Connect Biopharma expected to report topline data from both Phase 2 Seabreeze STAT studies around mid-2026.
Risks & what to watch (4)›
Key risks
- No approved products — Revenue of $2.8M as of 2026-06-30 indicates no commercial product sales [sec].
- Operating losses — Net income of -$17.3M as of 2026-06-30 reflects ongoing R&D spending without offsetting revenue [sec].
- Phase 3 execution risk — Positive Phase 2 data require confirmation in larger registrational trials; FDA discussions are planned but not yet concluded [news · 2026-09-30].
- Competitive standard of care — Existing treatments (bronchodilators, corticosteroids) are established for acute exacerbations [pipeline].
What to watch
- FDA feedback on Phase 3 registrational program for rademikibart in COPD, expected after September 2026 [news · 2026-09-30].
- Initiation and enrollment of Phase 3 trials for rademikibart in asthma and/or COPD.
- Cash burn rate and any additional financing rounds, given net losses of -$17.3M as of 2026-06-30 [sec].
- Potential partnership or milestone payments from Simcere for rademikibart in Greater China [pipeline].
Sources: Catalysts · News · Pipeline · Generated October 12, 2026 · How we verify sources →
Run Connect Biopharma Holdings Ltd through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Connect Biopharma Holdings Ltd facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.62 · 0% dilution
Lead: Phase 2
1 candidate
No upcoming catalysts tracked
1 buy · 0 sells (180d)
Pipeline
Regulatory
Financials
Short Interest
as of May 20, 2026- % of float
- 3.0%
- Days to cover
- 2.8
- Shares short
- 1,134,300
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CNTB short interestFrequently asked questions
What is the AI investment thesis for Connect Biopharma Holdings Ltd?
Connect Biopharma Holdings Ltd (CNTB) is a clinical-stage biopharmaceutical company developing rademikibart, a next-generation anti-IL-4Rα antibody, for acute exacerbations in asthma and COPD, with positive Phase 2 topline data reported in September 2026.
What is Connect Biopharma Holdings Ltd's lead drug candidate?
Connect Biopharma Holdings Ltd's most advanced tracked candidate is rademikibart (Phase 2) for Asthma Acute.
Who is the CEO of Connect Biopharma Holdings Ltd?
Dr. Barry David Quart Pharm.D. is the chief executive officer of Connect Biopharma Holdings Ltd (CNTB).
Where is Connect Biopharma Holdings Ltd headquartered?
Connect Biopharma Holdings Ltd (CNTB) is headquartered in San Diego, CA, United States.
What therapeutic areas does Connect Biopharma Holdings Ltd focus on?
Connect Biopharma Holdings Ltd develops therapies across Oncology, Respiratory.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.